BioPharmSignal logoBioPharmSignal

Biotech News

Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV)

Enanta Pharmaceuticals (ENTA)Enanta PharmaceuticalsClinical readout

Global Phase 2b/3 Study Will Evaluate Symptom Duration and Hospitalization Rates in Adult Outpatients at High Risk of Severe Outcomes from RSV Topline Phase 2b Data Expected in 2027 WATERTOWN, Mass. --(BUSINESS WIRE)--Oct. 26, 2026-- Enanta Pharmaceuticals, Inc.

Related news

ENTAEnanta Pharmaceuticals2026-10-13 11:00 EST

Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026

SCYXSCYNEXIS2026-10-06 11:30 EST

SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

ATYRaTyr Pharma2026-10-29 12:00 EST

aTyr Pharma Announces Publication of Results from the Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis in The Lancet Respiratory Medicine

BMYBMYBristol-Myers Squibb Company2026-11-06 21:00 EST

Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) for Camzyos (mavacamten) at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions

JNJJohnson & Johnson2026-10-25 14:24 EST

Subcutaneous RYBREVANT®▼ (amivantamab) demonstrates 77% overall response rate in first-line treatment of patients with certain types of advanced head and neck cancer

BMYBMYBristol-Myers Squibb Company2026-10-23 11:30 EST

Izalontamab Brengitecan (Iza-Bren) Reduced Risk of Disease Progression or Death by 59% versus Chemotherapy in Patients with Advanced HR+/HER2- Breast Cancer in Phase 3 PANKU-Breast01 Study

ARGXArgenx2026-10-08 05:00 EST

argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease

ENTAEnanta Pharmaceuticals2026-11-04 12:00 EST

Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences

JNJJohnson & Johnson2026-10-24 13:01 EST

Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk localised or locally advanced prostate cancer

SCYXSCYNEXIS2026-10-22 12:00 EST

SCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal Diseases

View all latest news

Enanta Pharmaceuticals

Small-Molecule Research Platform Enanta Pharmaceuticals discovers and develops oral small molecules for virology and immunology. Its portfolio applies structure-based drug design to targets that may support convenient, once-daily treatment. EDP-978 KIT Inhibitor EDP-978 is an oral KIT inhibitor in Phase 1 development for chronic...

Recent company news

ENTAEnanta Pharmaceuticals2026-11-04 12:00 EST

Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences

ENTAEnanta Pharmaceuticals2026-10-28 11:00 EST

Enanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D. After 23 Years of Company Leadership

ENTAEnanta Pharmaceuticals2026-10-26 11:00 EST

Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV)

ENTAEnanta Pharmaceuticals2026-10-13 11:00 EST

Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026

ENTAEnanta Pharmaceuticals2026-09-01 11:00 EST

Enanta Pharmaceuticals to Participate in September Investor Conferences

Stock data

Close
10.08 USD
Market cap
349.81M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States